Market Update,FDA removed five peptide bulk drug substances from Category 2

The FDA bulk drug substances list is a critical document for compound pharmacies and healthcare professionals, outlining which drug substances are permissible for use in compounding under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. A significant area of focus and recent evolution within this list pertains to peptides, particularly those designated under Category 2. Understanding the nuances of the FDA Category 2 classification, especially as it pertains to peptides and the events of 2023, is crucial for regulatory compliance and patient safety.

Category 2 on the FDA's list of bulk drug substances generally refers to bulk drug substances that the FDA has evaluated and determined to present significant safety risks. This designation can impact their availability for compounding. In late 2023, the FDA previously categorized more than a dozen peptides as category 2 substances, a move that significantly affected numerous popular peptides. This reclassification effectively placed many of these substances on a list that raised concerns for compounding.

The FDA's Category 2 peptide landscape has been dynamic. For instance, in October 2024, the FDA removed five peptide bulk drug substances from Category 2, impacting their compounding availability. These specific five peptide bulk drug substances included Thymosin Alpha-1 (TA-1), CJC-1295, Ipamorelin, Pentadecapeptide, and Semax (heptapeptide). However, it's important to note that as of early 2026, there has been no FDA announcement confirming removal of any peptide from Category 2 of the Section 503A bulk drug substances list beyond these specific instances.

The FDA's Category 2 peptide list has included compounds such as BPC-157, Ipamorelin, and Melanotan II, which were identified as posing significant safety risks, thus affecting their compounding status. The FDA's rationale for placing substances in Category 2 often stems from identified safety concerns, making them ineligible for use in compounding under certain conditions.

The year 2023 marked a pivotal moment in this regulatory evolution. In September of 2023, the FDA removed 17 drug substances from consideration for the 503A Bulk Substances List by redesignating them as Category 2. This action was part of a broader effort to assess the safety and efficacy of bulk drug substances used in compounding. Furthermore, in late 2023, the FDA updated its bulk drug substances list, moving 19 popular peptides from Category 1 to Category 2. This reclassification meant that these peptides, including well-known ones like BPC-157 and Thymosin Alpha-1, were now subject to stricter scrutiny.

Looking ahead, regulatory bodies and industry stakeholders are continually evaluating these bulk drug substances. For example, an FDA advisory committee was scheduled to discuss action on unapproved drug substances, including several peptides. Specifically, the PCAC (Pharmacy Compounding Advisory Committee) was to consider seven peptides for potential inclusion on the Section 503A Bulk Drug Substances List in July 2026. Among those expected to be reviewed are BPC-157, KPV, MOTs-C, Emideltide (DSIP), Epitalon, Semax (heptapeptide), and TB-500.

It is crucial for professionals to stay informed about these evolving regulations. The FDA Category 2 designation is not static, and updates can occur. Resources such as the FDA's list of bulk drug substances and official FDA announcements are essential for accurate information. The distinction between different categories is vital: Category 1 typically involves bulk drug substances under evaluation, Category 2 concerns bulk drug substances that raise significant safety concerns, and Category 3 relates to bulk drug substances nominated without adequate support for FDA evaluation.

The complexity of the FDA Category 2 landscape, particularly concerning peptides, highlights the importance of diligent research and adherence to regulatory guidelines. For those seeking information on the fda category 2 bulk drug substances peptides list 2023 2024, consulting official FDA publications and reputable industry resources is paramount. The ongoing reclassification and evaluation of these substances underscore the FDA's commitment to ensuring the safety and integrity of compounded medications.